Stacy L ChinFounder, KeepYourEquity · I get the government to write you checks

Unlock Biosecurity & Biotech Funding: Startups Get Ready!

10 Jul 2026 · 1 min

Watch on YouTube

0:40

In this concise briefing, Stacy L. Chin outlines the most promising funding pathways for biotech startups. She first highlights a set of SBIR‑eligible innovation lanes—infectious‑disease work, diagnostics, synthetic biology, and real‑time biosurveillance—encouraging founders to explore Small Business Innovation Research programs. Next, she points to the hot market of precision medicine and advanced therapeutics, especially cell‑, gene‑, and RNA‑based platforms, noting that while venture capital has traditionally funded these, VC money is tightening. Finally, she explains that federal agencies—NIH, the Department of Defense, and ARPA‑H—are actively stepping in to fund curated therapies targeting cancer, neurodegeneration, and rare diseases, offering an alternative source of capital for advanced‑therapy startups.

Chapters

If your startup touches on infectious diseases, diagnostics, synthetic biology, or real-time biosurveillance, this is your lane. And don't forget, these are also SBIR-eligible innovations, so make sure to look into that as well. Number 2 is precision medicine and advanced therapeutics, and this is especially a hot topic with cell gene and RNA-based platforms. Now I know what you're thinking— isn't VC funding a better fit for these advanced therapies? Perhaps, but they're also drying up, and that's why the federal government is stepping in. So NIH, DOD, and ARPA-H are actively funding startups that can deliver curated therapies, especially in cancer, neurodegeneration, and rare diseases.